Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA. 

Biotechnology

Health Care

Life Sciences

Zura Bio Limited (Nasdaq: ZURA)

Someit Sidhu

Michael Howell

Kiran Nistala

Sandeep Kulkarni

Rob Lisicki

Verender Badial

Kim Davis

Gary Whale

The Leadership Team at Zura Bio Limited (Nasdaq: ZURA) is responsible for guiding the strategic direction of the company, ensuring the successful development of its clinical-stage assets for immune and inflammatory disorders. This team oversees critical functions including legal, finance, scientific research, medical affairs, operations, technology, and executive management. Together, they work to advance Zura Bio's portfolio of therapeutic candidates through clinical trials and towards market readiness, aiming to demonstrate their efficacy, safety, and dosing convenience.

Leadership Team

Operations and Executive Planning

Leadership Team

About

Team members

Other teams at Zura Bio Limited (Nasdaq: ZURA)

Operations and Executive Planning